Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

529 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study.
Gori S, Clavarezza M, Siena S, Foglietta J, Tarenzi E, Giordano M, Molino A, Graiff C, Fusco V, Alabiso O, Baldini E, Gamucci T, Altavilla G, Dondi D, Venturini M. Gori S, et al. Among authors: baldini e. BMC Cancer. 2012 Apr 30;12:158. doi: 10.1186/1471-2407-12-158. BMC Cancer. 2012. PMID: 22545982 Free PMC article.
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Conte PF, Guarneri V, Bruzzi P, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M, Rosso R, Mammoliti S, Carnino F, Giannessi P, Costantini M, Moyano A, Baldini E; Gruppo Oncologico Nord Ovest. Conte PF, et al. Among authors: baldini e. Cancer. 2004 Aug 15;101(4):704-12. doi: 10.1002/cncr.20400. Cancer. 2004. PMID: 15305399 Free article. Clinical Trial.
Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM).
Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Beretta GD, Caffo O, Caroti C, Crinò L, De Laurentiis M, Dinota A, Di Vito F, Gebbia V, Giustini L, Graiff C, Guida M, Lelli G, Lombardo M, Muggiano A, Puglisi F, Romito S, Salvagno L, Tagliaferri P, Terzoli E, Venturini M; AIOM Working Group Interaction with Regional Sections (2007-2009). Gori S, et al. Among authors: baldini e. Tumori. 2010 Nov-Dec;96(6):1010-5. Tumori. 2010. PMID: 21388067
Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM).
Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Barbato E, Beretta GD, Bravi S, Caffo O, Canobbio L, Carrozza F, Cinieri S, Cruciani G, Dinota A, Gebbia V, Giustini L, Graiff C, Molino A, Muggiano A, Pandoli G, Puglisi F, Tagliaferri P, Tomao S, Venturini M; AIOM Working Group "Interactions with Regional Sections" (2009-2011). Gori S, et al. Among authors: baldini e. Tumori. 2011 Jul-Aug;97(4):442-8. doi: 10.1177/030089161109700405. Tumori. 2011. PMID: 21989431
Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM).
Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Barbato E, Beretta GD, Bravi S, Caffo O, Canobbio L, Carrozza F, Cinieri S, Cruciani G, Dinota A, Gebbia V, Giustini L, Graiff C, Molino A, Muggiano A, Pandoli G, Puglisi F, Tagliaferri P, Tomao S, Lunardi G, Venturini M; AIOM Working Group “Interaction with Regional Sections” (2009-2011). Gori S, et al. Among authors: baldini e. Tumori. 2013 Jan-Feb;99(1):35-8. doi: 10.1177/030089161309900106. Tumori. 2013. PMID: 23548997
Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.
Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, De Tursi M, Grassadonia A, Mazzilli L, Iacobelli S, Gamucci T, Vici P; “FOLLOW-UP” Study Group. Natoli C, et al. PLoS One. 2014 Apr 8;9(4):e94063. doi: 10.1371/journal.pone.0094063. eCollection 2014. PLoS One. 2014. PMID: 24714591 Free PMC article.
Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.
Tiseo M, Boni L, Ambrosio F, Camerini A, Vitale MG, Baldini E, Cinieri S, Zanelli F, Defraia E, Passalacqua R, Crino L, Dazzi C, Tibaldi C, Turolla GM, D'Alessandro V, Zilembo N, Riccardi F, Ardizzoni A; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Tiseo M, et al. Among authors: baldini e. Clin Lung Cancer. 2015 Jan;16(1):67-70. doi: 10.1016/j.cllc.2014.09.001. Epub 2014 Sep 28. Clin Lung Cancer. 2015. PMID: 25450879 Clinical Trial.
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.
Farolfi A, Scarpi E, Rocca A, Mangia A, Biglia N, Gianni L, Tienghi A, Valerio MR, Gasparini G, Amaducci L, Faedi M, Baldini E, Rubagotti A, Maltoni R, Paradiso A, Amadori D. Farolfi A, et al. Among authors: baldini e. Eur J Cancer. 2015 Sep;51(14):1874-81. doi: 10.1016/j.ejca.2015.07.003. Epub 2015 Jul 20. Eur J Cancer. 2015. PMID: 26206258 Clinical Trial.
529 results